• South Korea Pharma inlicensing strategy provides financing opportunites to development stage companies with novel late stage products and devices
• Business Opportunities and Analysis reports provide new ideas and directions
• BDSI and TTY enter into a licensing agreement for Bema Fentanyl for the Taiwan market
• Alfresa Pharmaceutical Corporation of Japan entered into a licensing and supply agreement for development and marketing of tetrabenazine (Xenazine®) in Japan with Canada's Biovail Corporation
• BDSI and KunWha Pharmaceutical Co. entered into a licensing agreement for Bema Fentanyl for the South Korean market

ProPharma Partners was founded in 1998 to provide a broad range of advisory and consulting services to the Biotechnology and Pharmaceutical Industries. Over the past 12 years ProPharma has successfully worked with hundreds of companies in providing:

• Product and technology in-licensing and out-licensing in North America, Europe and Japan
• Valuation determinations using discounted cash flow analysis and comparables
• Due diligence assessments of pharmaceutical products and development stage companies
• Preclinical and clinical management services for a wide range of therapeutic entities
• Early stage financing strategies

ProPharma is present in the major Pharmaceutical markets of North America, Europe and Japan as well as South Korea. Areas of therapeutic expertise include oncology, immunology, inflammation, pain, CNS, metabolic diseases, cardiovascular disorders, anti-infectives, respiratory diseases and dermatology.

ProPharma employs a proven and successful multidisciplinary team approach to quickly and efficiently assist client companies in achieving their business goals and initiatives.

• James Chubb, Ph.D.
• Peter Cozens, Ph.D.
• Geoff Kitson, MD.
• Paulo Rangel, MBA.
• Andy Baxter, Ph.D.
• Phil Nichols, MD.
• Jill Rasmussen, MD.
• Paul Cossum, Ph.D.
• Yasuhiro Takahashi
• Mitsutoshi Hamano, Ph.D.
• Hirouki Terayama, Ph.D.